用于治疗绝经的组织选择性雌激素复合物（巴多昔芬/共轭雌激素）
The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause.
作者信息
Lello Stefano, Capozzi Anna, Scambia Giovanni
机构信息
Department of Woman and Child Health, Policlinico Gemelli Foundation, Largo Agostino Gemelli, Roma, Italy.
出版信息
Int J Endocrinol. 2017;2017:5064725. doi: 10.1155/2017/5064725. Epub 2017 Dec 5.
Abstract
The tissue-selective estrogen complex (TSEC) pairs conjugated estrogens (CE) with a selective estrogen receptor modulator (SERM), bazedoxifene acetate (BZA). A 2-year treatment with the TSEC improved vasomotor symptoms, quality of life, and vaginal atrophy in healthy postmenopausal women. In addition, the TSEC prevented vertebral and hip bone loss without increasing mammographic density, breast tenderness, the risk of myocardial infarction, stroke, or venous thromboembolism. Finally, the BZA 20 mg/CE 0.45 mg dose did not increase the risk of endometrial hyperplasia. Based on these findings, the TSEC can be considered as a first-line treatment for symptomatic postmenopausal women.
摘要
组织选择性雌激素复合物（TSEC）将共轭雌激素（CE）与选择性雌激素受体调节剂（SERM）醋酸巴多昔芬（BZA）相结合。对健康绝经后女性进行为期两年的TSEC治疗可改善血管舒缩症状、生活质量及阴道萎缩。此外，TSEC可预防椎体和髋部骨质流失，且不会增加乳房X线密度、乳房压痛、心肌梗死、中风或静脉血栓栓塞的风险。最后，20毫克BZA/0.45毫克CE的剂量不会增加子宫内膜增生的风险。基于这些发现，TSEC可被视为有症状绝经后女性的一线治疗方法。
相似文献
1
The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause.用于治疗绝经的组织选择性雌激素复合物（巴多昔芬/共轭雌激素）
Int J Endocrinol. 2017;2017:5064725. doi: 10.1155/2017/5064725. Epub 2017 Dec 5.
2
Tissue-selective estrogen complexes for postmenopausal women.用于绝经后妇女的组织选择性雌激素复合物。
Maturitas. 2013 Nov;76(3):213-20. doi: 10.1016/j.maturitas.2013.06.003. Epub 2013 Jul 11.
3
Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.共轭雌激素/巴多昔芬的研发，这是首个用于治疗更年期潮热和绝经后骨质流失的组织选择性雌激素复合物（TSEC）。
Steroids. 2014 Nov;90:71-81. doi: 10.1016/j.steroids.2014.06.004. Epub 2014 Jun 11.
4
Selective estrogen modulators in menopause.绝经中的选择性雌激素调节剂
Minerva Ginecol. 2013 Dec;65(6):621-30.
5
Treating menopausal symptoms with a tissue-selective estrogen complex.使用组织选择性雌激素复合物治疗更年期症状。
Gend Med. 2011 Apr;8(2):57-68. doi: 10.1016/j.genm.2011.03.008.
6
Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.巴多昔芬与共轭马雌激素：一种用于管理血管舒缩症状及预防绝经相关骨质疏松症的复方产品。
Pharmacotherapy. 2016 May;36(5):548-61. doi: 10.1002/phar.1749. Epub 2016 May 11.
7
Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.比戈洛苯/结合雌激素治疗绝经症状和预防骨质疏松症。
Climacteric. 2012 Oct;15(5):411-8. doi: 10.3109/13697137.2012.696289. Epub 2012 Aug 1.
8
Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy.将巴多昔芬/结合雌激素纳入当前的更年期治疗模式。
Int J Womens Health. 2012;4:129-40. doi: 10.2147/IJWH.S29346. Epub 2012 Mar 28.
9
What do TSECs provide in the menopausal hormone therapy?增殖期子宫内膜细胞在绝经激素治疗中发挥什么作用？
Gynecol Endocrinol. 2018 Oct;34(10):826-832. doi: 10.1080/09513590.2018.1474869. Epub 2018 May 23.
10
Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.组织选择性药物：选择性雌激素受体调节剂与组织选择性雌激素复合物
Menopause Int. 2010 Sep;16(3):121-8. doi: 10.1258/mi.2010.010033.
引用本文的文献
1
Deciphering the role of classical oestrogen receptor in insulin resistance and type 2 diabetes mellitus: From molecular mechanism to clinical evidence.解读经典雌激素受体在胰岛素抵抗和2型糖尿病中的作用：从分子机制到临床证据
Bioimpacts. 2024 Aug 4;15:30378. doi: 10.34172/bi.30378. eCollection 2025.
2
Using estrogen and progesterone to treat premenstrual dysphoric disorder, postnatal depression and menopausal depression.使用雌激素和孕激素治疗经前烦躁障碍、产后抑郁症和更年期抑郁症。
Front Pharmacol. 2025 Feb 20;16:1528544. doi: 10.3389/fphar.2025.1528544. eCollection 2025.
3
Exploring the effects of estrogen deficiency and aging on organismal homeostasis during menopause.探索雌激素缺乏和衰老对更年期机体稳态的影响。
Nat Aging. 2024 Dec;4(12):1731-1744. doi: 10.1038/s43587-024-00767-0. Epub 2024 Dec 13.
4
Clinical Data for Parametrization of Bone Models Incorporating Cell-Cytokine Dynamics: A Systematic Review of Literature.纳入细胞-细胞因子动力学的骨模型参数化临床数据：文献系统评价
Front Bioeng Biotechnol. 2022 Jul 12;10:901720. doi: 10.3389/fbioe.2022.901720. eCollection 2022.
5
Hormonal Agents for the Treatment of Depression Associated with the Menopause.用于治疗与绝经相关的抑郁症的激素药物。
Drugs Aging. 2022 Aug;39(8):607-618. doi: 10.1007/s40266-022-00962-x. Epub 2022 Jul 30.
6
Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO.意大利绝经学会（SIE）、意大利骨与矿物质代谢学会（SIOMMMS）和意大利绝经与卵巢学会（SIGO）关于绝经后女性使用激素替代疗法治疗骨质疏松症的共识声明。
J Endocrinol Invest. 2019 May;42(5):609-618. doi: 10.1007/s40618-018-0978-x. Epub 2018 Nov 19.
本文引用的文献
1
The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials.共轭雌激素/巴多昔芬疗法对绝经后女性体重的影响：五项随机、安慰剂对照试验的汇总分析。
Menopause. 2016 Apr;23(4):376-82. doi: 10.1097/GME.0000000000000541.
2
Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.奥培米芬对外阴和阴道萎缩的中度或重度症状的影响。
Climacteric. 2016;19(1):60-5. doi: 10.3109/13697137.2015.1113517. Epub 2015 Nov 19.
3
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.选择性雌激素受体调节剂及结合雌激素/巴多昔芬联合疗法：对乳腺影响的综述
Post Reprod Health. 2015 Sep;21(3):112-21. doi: 10.1177/2053369115599090. Epub 2015 Aug 19.
4
A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials.来自选择性雌激素、绝经与治疗反应（SMART）试验的共轭雌激素/巴多昔芬对绝经后女性脂质参数影响的汇总分析。
J Clin Endocrinol Metab. 2015 Jun;100(6):2329-38. doi: 10.1210/jc.2014-2649. Epub 2015 Apr 20.
5
A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.一项为期7年的随机、安慰剂对照试验，评估巴多昔芬在绝经后骨质疏松症女性中的长期疗效和安全性：对骨密度和骨折的影响。
Menopause. 2015 Aug;22(8):806-13. doi: 10.1097/GME.0000000000000419.
6
Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.共轭雌激素/巴多昔芬的研发，这是首个用于治疗更年期潮热和绝经后骨质流失的组织选择性雌激素复合物（TSEC）。
Steroids. 2014 Nov;90:71-81. doi: 10.1016/j.steroids.2014.06.004. Epub 2014 Jun 11.
7
Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.巴多昔芬/共轭雌激素对子宫内膜和骨骼的影响：一项随机试验。
J Clin Endocrinol Metab. 2014 Feb;99(2):E189-98. doi: 10.1210/jc.2013-1707. Epub 2014 Jan 17.
8
Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action.结合马雌激素的药理学：疗效、安全性和作用机制。
J Steroid Biochem Mol Biol. 2014 Jul;142:16-29. doi: 10.1016/j.jsbmb.2013.10.011. Epub 2013 Oct 28.
9
Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial.使用巴多昔芬/结合雌激素治疗的睡眠参数和与健康相关的生活质量：一项随机试验。
Menopause. 2014 Mar;21(3):252-9. doi: 10.1097/GME.0b013e31829f0433.
10
Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture.巴多昔芬/共轭雌激素治疗有骨折风险女性雌激素缺乏症状和骨质疏松症的概况。
Drug Des Devel Ther. 2013 Jul 22;7:601-10. doi: 10.2147/DDDT.S47807. Print 2013.
Zotero 插件